For example, studies from ourgroup demonstrated that treatment with the PPARα agonist, gemfibrozil, was able to prevent the accumulation ofatherosclerotic plaque in apolipoprotein E (apoE) knockout (KO) mice, a model inwhich PPARα agonistshave no effect on severe dyslipidaemia [8]. The gene discussed is PPARA; the disease is inherited lipid metabolism disorder.